NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 3 PAGES Amendment No. 2

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below, to use such material for the purpose(s) The licensee to receive acquire, possess, and transfer byproduct, source, and special nuclear material designated below, to use such material for the purpose(s) The licensee to receive acquire, possess, and transfer byproduct, source, and special nuclear material designated below, to use such material for the purpose(s) The licensee to receive acquire, possess, and transfer byproduct, source, and special nuclear material designated below, to use such material for the purpose(s) The licensee to receive acquire, possess, and transfer byproduct, source, and special nuclear material designated below, to use such material for the purpose(s) The licensee to receive acquire, possess, and transfer byproduct, source, and special nuclear material designated below, to use such material for the purpose (s) and transfer byproduct, source, and special nuclear material designated below, to use such material for the purpose (s) and transfer byproduct, source, and special nuclear material designated below, to use such material for the purpose (s) and transfer byproduct and tran and at the place(s) designated below, to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

-				-
	>	0	5 7	
	Any byproduct material permitted by 10 CFR 35.300	Byproduct, source, and/or special nuclear material	Licensee 1. Precise Radiation Oncology Center 2. P.O. Box 1589 Bayamon, PR 00960	
	>	7.	Licensee ncology C	
	Any	Chemi	enter	
()	SITED S	Chemical and/or physical form	5 NO 5 1 1	now of ficienties in ellec
CONDITIONS	A. 400 millicuries total	Maximum amount that licensee may possess at any one time under this license	In accordance with email dated January 23, 2019. 3. License number: 52-35129-01 is amended in its entirety to read as follows:	of herealter in effect and to any conditions specified below.
	A. For any therapy procedure permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75, except those involving iodine-131.	isee 9. Authorized use	4. Expiration Date: May 31, 2024 5. Docket No.: 030-38713 Reference No.:	

10.

Davila, Bayamon, Puerto Rico

The Radiation Safety Officer (RSO) for this license is Adriana Cordova Ayuso, M.S., DABR.

Licensed material may be used or stored at the licensee's facilities located at Carratera Marginal #2, Esquina 3B, Suite G1, Urb. Hermanas

12. Licensed material shall only be used by, or under the supervision of:

Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

8 The following individuals are authorized users for the material and medical uses as indicated: Authorized User(M.D.,D.O.,etc.)

Material and Use

Parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon Parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required.

Lawrence L. Sheplan Olsen, M.D. energy less than 150 keV for which a written directive is required. energy less than 150 keV for which a written directive is required. Parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon

Roberto J. Santiago

Louisa V. Marcial, M.D.

Javier Lopez Araujo, M.D.

Parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required

- 13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to correspondence are more restrictive than the regulations. licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the
- A. Application date February 6, 2014 [ML14052A139]
- Letter dated May 12, 2014 [ML14140A707]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

201SSIWW

By: 10507 A
Robert Gallaghar
Region 1

Date: April 1, 2019